ArticleJAMA network open2025
Five-Year Functional Outcomes Among Patients Surviving Aneurysmal Subarachnoid Hemorrhage.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic Review of Direct Hospital Costs Associated with Aneurysmal Subarachnoid Hemorrhage Management.Neurocritical care · 2026Pooled it
- Non-contrast computed tomography at the end of the acute care phase as an additional prognostic tool after aneurysmal subarachnoid hemorrhage.Neurosurgical review · 2026Article
- Admission Inflammatory Blood Cell Ratios as Prognostic Markers of Functional Outcome After Aneurysmal Subarachnoid Hemorrhage: A Single-Center Retrospective Cohort Study.Biomedicines · 2026Article
- The impact of smoking on aneurysmal rupture in female patients: a nationwide retrospective cohort study.Neurosurgical review · 2026Article
- Cost-utility framework to evaluate therapeutic interventions targeting reduction in cerebral infarction among aneurysmal subarachnoid hemorrhage patients.Neurosurgical review · 2026Article
- Longitudinal trajectories of functional outcome following aneurysmal subarachnoid hemorrhage: a retrospective study.Critical care (London, England) · 2026Article
- Functional recovery patterns from discharge to 12 months after endovascular treatment for aneurysmal subarachnoid hemorrhage: a multicenter cohort study.Frontiers in neuroscience · 2026Article
- Molecular Targets for Intracranial Aneurysm Treatment.International journal of molecular sciences · 2025Review
- Postdischarge participation and functional outcomes across three common stroke subtypes based on the exploratory retrospective study.Scientific reports · 2025Article
- Beyond the bleed: complications after aneurysmal subarachnoid hemorrhage. Pathophysiology, clinical implications, and management strategies: a review.Critical care (London, England) · 2025Review
- Impact of acute alcohol intoxication and alcohol dependence on outcomes after subarachnoid hemorrhage.Acta neurochirurgica · 2025Article
- Rising burden of subarachnoid hemorrhage linked to high systolic blood pressure among young and middle-aged populations: temporal trends and global implication.Frontiers in human neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Longitudinal changes in functional levels can provide valuable information about disability. However, longitudinal outcomes in aneurysmal subarachnoid hemorrhage (aSAH) have not been well reported, which could provide insight into appropriate management and information for patients experiencing disability. Objective: To investigate the 5-year prognosis and functional outcomes of patients with aSAH. Design, Setting, and Participants: This retrospective cohort study used data of patients with aSAH from the Korean Stroke Cohort for Functioning and Rehabilitation study up to 5 years after onset. Data were collected from August 2012 through May 2015 in 9 different hospitals in Korea. Data were analyzed from September 2023 through January 2024. Exposure: Patients with aSAH surviving at least 7 days after onset. Main Outcomes and Measures: Assessments were performed serially from 7 days to 5 years after onset. Prognosis, measured by the modified Rankin scale (mRS) in terms of positive outcome (mRS score of 0 or 1), and mortality were analyzed. In addition, sequential functional outcomes were assessed using the Functional Independence Measure (FIM) in survivors of aSAH at 5 years after onset. Multiple imputation method was used to handle missing data. Wilcoxon signed-rank test and paired t test were used to analyze differences in functional measurements between each follow-up period. Additionally, a generalized mixed-effects model was used to analyze the longitudinal trajectory of the FIM. Results: A total of 338 patients with aSAH (mean [SD] age, 56.3 [13.0] years; 207 female [61.2%]) were included. Among survivors of aSAH at 7 days, the 5-year mortality rate was 8.3% (28 participants). The distribution of mRS significantly improved until 4 years and then plateaued, with 180 (53.3%) and 77 (22.8%) patients reporting an mRS score of 0 and 1, respectively. FIM showed a significant improvement up to 4 years (mean [SD] score, 118.9 [18.7]) and then plateaued. Conclusions and Relevance: In this cohort study, the functional outcomes in patients with aSAH continued to improve up to 4 years after onset, with the majority of participants showing favorable outcomes without significant disability, suggesting that proper long-term assessment is needed and appropriate management should be emphasized to maximize potential outcomes of patients with aSAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.